{"id":982902,"date":"2026-07-20T11:58:23","date_gmt":"2026-07-20T15:58:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-shareholder-alert-psnl-shareholders-interested-in-pursuing-potential-claims-should-contact-julie-holleman-regarding-proposed-sale-to-tempus\/"},"modified":"2026-07-20T11:58:23","modified_gmt":"2026-07-20T15:58:23","slug":"personalis-shareholder-alert-psnl-shareholders-interested-in-pursuing-potential-claims-should-contact-julie-holleman-regarding-proposed-sale-to-tempus","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-shareholder-alert-psnl-shareholders-interested-in-pursuing-potential-claims-should-contact-julie-holleman-regarding-proposed-sale-to-tempus\/","title":{"rendered":"PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie &amp; Holleman Regarding Proposed Sale to Tempus"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW YORK, July  20, 2026  (GLOBE NEWSWIRE) &#8212; Julie &amp; Holleman LLP, a nationally recognized shareholder rights firm, is investigating the proposed acquisition of Personalis, Inc. (Nasdaq: PSNL) by Tempus AI, Inc. (Nasdaq: TEM), an existing Personalis shareholder and strategic partner.<\/p>\n<p>For a free consultation, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7EV_fcSR_3OHZdX1oGjEea9OL_HraWooklwCPyfC8bu-jabzrNE8IVxrsKDwiLhgdTnXumATZWw9UKEC3CVWO_BWJ88DpE9mCgnnY4Hn8NLQMSy1XB9iXn4ZvNFBK9sNXYVfKefpAa5J_oOQZliIUQ==\" rel=\"nofollow\" target=\"_blank\">https:\/\/julieholleman.com\/personalis-inc\/<\/a>. You may also contact partner Scott Holleman at (929) 415-1020 or by email at scott@julieholleman.com.<\/p>\n<p>Personalis is a precision oncology company that develops advanced genomic tests designed to detect and monitor cancer. The company has established itself as a leader in molecular residual disease (&#8220;MRD&#8221;) testing, a rapidly growing market with significant long-term potential.<\/p>\n<p>On July 20, 2026, Personalis announced that it had agreed to be acquired by Tempus for consideration valued at $16.25 per share. Tempus, however, is not a typical third-party acquirer. The company already owns a significant equity stake in Personalis through an existing strategic relationship that began in 2023 and has worked closely with Personalis in commercializing its MRD technology.<\/p>\n<p>Julie &amp; Holleman is investigating whether Personalis&#8217; public shareholders are receiving fair value for their shares. The firm is particularly concerned that Tempus&#8217; preexisting ownership position and strategic relationship with Personalis may have created conflicts of interest during the sale process. The firm is also evaluating whether the merger consideration adequately reflects Personalis&#8217; long-term value as demand for MRD testing continues to grow.<\/p>\n<p>FIRM INFORMATION<\/p>\n<p>Julie &amp; Holleman is a boutique law firm that focuses on shareholder litigation, including derivative actions, mergers and acquisitions cases, securities fraud class actions, and corporate investigations. The firm\u2019s attorneys litigate in state and federal courts across the nation and have helped secure hundreds of millions of dollars for aggrieved companies and their shareholders. For more information about the firm, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7kZyUTBhwHxHgfdezY-S-xLhY12digskGBdeddptDkVoM3sFdWyz9fHWAAj3OQQrsfekhoe0l1fPABliQONGIyUz6QhIFL4nKBbmQNgwIqA=\" rel=\"nofollow\" target=\"_blank\">www.julieholleman.com<\/a>. This notice may constitute attorney advertising.<\/p>\n<p>Julie &amp; Holleman LLP<br \/>W. Scott Holleman, Esq.<br \/>157 East 86th Street<br \/>4th Floor<br \/>New York, NY 10028<br \/>(929) 415-1020<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7kZyUTBhwHxHgfdezY-S-xLhY12digskGBdeddptDkVemfjyPtplMYbH6tvo218P_jRBem2M9LbTGO9YTaSGgtYgRZKHZLe2mmQAWH5HnhU=\" rel=\"nofollow\" target=\"_blank\">www.julieholleman.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NDgyMCM3NzEzNzgwIzIyOTI2MzI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NjMwNDQ0YWUtYjVkMS00YTUzLWI5Y2UtOTFhZjA0NGEwOTRkLTEzMDQxODItMjAyNi0wNy0yMC1lbg==\/tiny\/Julie-Holleman-LLP.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) &#8212; Julie &amp; Holleman LLP, a nationally recognized shareholder rights firm, is investigating the proposed acquisition of Personalis, Inc. (Nasdaq: PSNL) by Tempus AI, Inc. (Nasdaq: TEM), an existing Personalis shareholder and strategic partner. For a free consultation, please visit https:\/\/julieholleman.com\/personalis-inc\/. You may also contact partner Scott Holleman at (929) 415-1020 or by email at scott@julieholleman.com. Personalis is a precision oncology company that develops advanced genomic tests designed to detect and monitor cancer. The company has established itself as a leader in molecular residual disease (&#8220;MRD&#8221;) testing, a rapidly growing market with significant long-term potential. On July 20, 2026, Personalis announced that it had agreed to be acquired by Tempus for consideration valued &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-shareholder-alert-psnl-shareholders-interested-in-pursuing-potential-claims-should-contact-julie-holleman-regarding-proposed-sale-to-tempus\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie &amp; Holleman Regarding Proposed Sale to Tempus&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-982902","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie &amp; Holleman Regarding Proposed Sale to Tempus - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-shareholder-alert-psnl-shareholders-interested-in-pursuing-potential-claims-should-contact-julie-holleman-regarding-proposed-sale-to-tempus\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie &amp; Holleman Regarding Proposed Sale to Tempus - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) &#8212; Julie &amp; Holleman LLP, a nationally recognized shareholder rights firm, is investigating the proposed acquisition of Personalis, Inc. (Nasdaq: PSNL) by Tempus AI, Inc. (Nasdaq: TEM), an existing Personalis shareholder and strategic partner. For a free consultation, please visit https:\/\/julieholleman.com\/personalis-inc\/. You may also contact partner Scott Holleman at (929) 415-1020 or by email at scott@julieholleman.com. Personalis is a precision oncology company that develops advanced genomic tests designed to detect and monitor cancer. The company has established itself as a leader in molecular residual disease (&#8220;MRD&#8221;) testing, a rapidly growing market with significant long-term potential. On July 20, 2026, Personalis announced that it had agreed to be acquired by Tempus for consideration valued &hellip; Continue reading &quot;PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie &amp; Holleman Regarding Proposed Sale to Tempus&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-shareholder-alert-psnl-shareholders-interested-in-pursuing-potential-claims-should-contact-julie-holleman-regarding-proposed-sale-to-tempus\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-20T15:58:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NDgyMCM3NzEzNzgwIzIyOTI2MzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-shareholder-alert-psnl-shareholders-interested-in-pursuing-potential-claims-should-contact-julie-holleman-regarding-proposed-sale-to-tempus\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-shareholder-alert-psnl-shareholders-interested-in-pursuing-potential-claims-should-contact-julie-holleman-regarding-proposed-sale-to-tempus\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie &amp; Holleman Regarding Proposed Sale to Tempus\",\"datePublished\":\"2026-07-20T15:58:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-shareholder-alert-psnl-shareholders-interested-in-pursuing-potential-claims-should-contact-julie-holleman-regarding-proposed-sale-to-tempus\\\/\"},\"wordCount\":335,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-shareholder-alert-psnl-shareholders-interested-in-pursuing-potential-claims-should-contact-julie-holleman-regarding-proposed-sale-to-tempus\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2NDgyMCM3NzEzNzgwIzIyOTI2MzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-shareholder-alert-psnl-shareholders-interested-in-pursuing-potential-claims-should-contact-julie-holleman-regarding-proposed-sale-to-tempus\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-shareholder-alert-psnl-shareholders-interested-in-pursuing-potential-claims-should-contact-julie-holleman-regarding-proposed-sale-to-tempus\\\/\",\"name\":\"PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie &amp; Holleman Regarding Proposed Sale to Tempus - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-shareholder-alert-psnl-shareholders-interested-in-pursuing-potential-claims-should-contact-julie-holleman-regarding-proposed-sale-to-tempus\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-shareholder-alert-psnl-shareholders-interested-in-pursuing-potential-claims-should-contact-julie-holleman-regarding-proposed-sale-to-tempus\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2NDgyMCM3NzEzNzgwIzIyOTI2MzI=\",\"datePublished\":\"2026-07-20T15:58:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-shareholder-alert-psnl-shareholders-interested-in-pursuing-potential-claims-should-contact-julie-holleman-regarding-proposed-sale-to-tempus\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-shareholder-alert-psnl-shareholders-interested-in-pursuing-potential-claims-should-contact-julie-holleman-regarding-proposed-sale-to-tempus\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-shareholder-alert-psnl-shareholders-interested-in-pursuing-potential-claims-should-contact-julie-holleman-regarding-proposed-sale-to-tempus\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2NDgyMCM3NzEzNzgwIzIyOTI2MzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2NDgyMCM3NzEzNzgwIzIyOTI2MzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-shareholder-alert-psnl-shareholders-interested-in-pursuing-potential-claims-should-contact-julie-holleman-regarding-proposed-sale-to-tempus\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie &amp; Holleman Regarding Proposed Sale to Tempus\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie &amp; Holleman Regarding Proposed Sale to Tempus - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-shareholder-alert-psnl-shareholders-interested-in-pursuing-potential-claims-should-contact-julie-holleman-regarding-proposed-sale-to-tempus\/","og_locale":"en_US","og_type":"article","og_title":"PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie &amp; Holleman Regarding Proposed Sale to Tempus - Market Newsdesk","og_description":"NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) &#8212; Julie &amp; Holleman LLP, a nationally recognized shareholder rights firm, is investigating the proposed acquisition of Personalis, Inc. (Nasdaq: PSNL) by Tempus AI, Inc. (Nasdaq: TEM), an existing Personalis shareholder and strategic partner. For a free consultation, please visit https:\/\/julieholleman.com\/personalis-inc\/. You may also contact partner Scott Holleman at (929) 415-1020 or by email at scott@julieholleman.com. Personalis is a precision oncology company that develops advanced genomic tests designed to detect and monitor cancer. The company has established itself as a leader in molecular residual disease (&#8220;MRD&#8221;) testing, a rapidly growing market with significant long-term potential. On July 20, 2026, Personalis announced that it had agreed to be acquired by Tempus for consideration valued &hellip; Continue reading \"PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie &amp; Holleman Regarding Proposed Sale to Tempus\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-shareholder-alert-psnl-shareholders-interested-in-pursuing-potential-claims-should-contact-julie-holleman-regarding-proposed-sale-to-tempus\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-20T15:58:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NDgyMCM3NzEzNzgwIzIyOTI2MzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-shareholder-alert-psnl-shareholders-interested-in-pursuing-potential-claims-should-contact-julie-holleman-regarding-proposed-sale-to-tempus\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-shareholder-alert-psnl-shareholders-interested-in-pursuing-potential-claims-should-contact-julie-holleman-regarding-proposed-sale-to-tempus\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie &amp; Holleman Regarding Proposed Sale to Tempus","datePublished":"2026-07-20T15:58:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-shareholder-alert-psnl-shareholders-interested-in-pursuing-potential-claims-should-contact-julie-holleman-regarding-proposed-sale-to-tempus\/"},"wordCount":335,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-shareholder-alert-psnl-shareholders-interested-in-pursuing-potential-claims-should-contact-julie-holleman-regarding-proposed-sale-to-tempus\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NDgyMCM3NzEzNzgwIzIyOTI2MzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-shareholder-alert-psnl-shareholders-interested-in-pursuing-potential-claims-should-contact-julie-holleman-regarding-proposed-sale-to-tempus\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-shareholder-alert-psnl-shareholders-interested-in-pursuing-potential-claims-should-contact-julie-holleman-regarding-proposed-sale-to-tempus\/","name":"PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie &amp; Holleman Regarding Proposed Sale to Tempus - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-shareholder-alert-psnl-shareholders-interested-in-pursuing-potential-claims-should-contact-julie-holleman-regarding-proposed-sale-to-tempus\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-shareholder-alert-psnl-shareholders-interested-in-pursuing-potential-claims-should-contact-julie-holleman-regarding-proposed-sale-to-tempus\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NDgyMCM3NzEzNzgwIzIyOTI2MzI=","datePublished":"2026-07-20T15:58:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-shareholder-alert-psnl-shareholders-interested-in-pursuing-potential-claims-should-contact-julie-holleman-regarding-proposed-sale-to-tempus\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/personalis-shareholder-alert-psnl-shareholders-interested-in-pursuing-potential-claims-should-contact-julie-holleman-regarding-proposed-sale-to-tempus\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-shareholder-alert-psnl-shareholders-interested-in-pursuing-potential-claims-should-contact-julie-holleman-regarding-proposed-sale-to-tempus\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NDgyMCM3NzEzNzgwIzIyOTI2MzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NDgyMCM3NzEzNzgwIzIyOTI2MzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-shareholder-alert-psnl-shareholders-interested-in-pursuing-potential-claims-should-contact-julie-holleman-regarding-proposed-sale-to-tempus\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie &amp; Holleman Regarding Proposed Sale to Tempus"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/982902","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=982902"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/982902\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=982902"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=982902"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=982902"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}